These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1130 related items for PubMed ID: 8124252

  • 21. Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: favorable outcome with BMT at first remission and HLA-matched unrelated donor.
    Chim CS, Lie AK, Liang R, Au WY, Kwong YL.
    Bone Marrow Transplant; 2007 Aug; 40(4):339-47. PubMed ID: 17572712
    [Abstract] [Full Text] [Related]

  • 22. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Ball E, Cook D, Andresen S, Kuczkowski E, Bolwell B.
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [Abstract] [Full Text] [Related]

  • 23. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
    Schots R, Van Riet I, Ben Othman T, Trullemans F, De Waele M, Van Camp B.
    Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
    [Abstract] [Full Text] [Related]

  • 24. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N, Badsberg JH, Lönnqvist B, Ringdén O, Volin L, Rajantie J, Nikoskelainen J, Keiding N.
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [Abstract] [Full Text] [Related]

  • 25. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

  • 26. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J.
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [Abstract] [Full Text] [Related]

  • 27. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SJ, Blume KG.
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
    [Abstract] [Full Text] [Related]

  • 28. Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia.
    Drobyski WR, Pelz C, Kabler-Babbitt C, Hessner M, Baxter-Lowe LA, Keever-Taylor CA.
    Biol Blood Marrow Transplant; 1998 Dec; 4(1):3-12. PubMed ID: 9701386
    [Abstract] [Full Text] [Related]

  • 29. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético.
    Carreras E, Tomás JF, Sanz G, Iriondo A, Boqué C, López J, Cabrera R, Sureda A, de Soria VG, Sierra J, Sanz MA, Torres A.
    Haematologica; 2000 May; 85(5):530-8. PubMed ID: 10800172
    [Abstract] [Full Text] [Related]

  • 30. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 31. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease.
    Moussalem M, Esperou Bourdeau H, Devergie A, Baruchel A, Ribaud P, Socie G, Parquet N, Traineau R, Hirsch I, Schaison G.
    Bone Marrow Transplant; 1995 Jun; 15(6):943-7. PubMed ID: 7581095
    [Abstract] [Full Text] [Related]

  • 32. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG, Warkentin PI, Strandjord SE, Abromowitch M, Bayever E, Harper JL, Coccia PF.
    Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
    [Abstract] [Full Text] [Related]

  • 33. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
    Hirabayashi N, Goto S, Ishii M, Yuge M, Mitsuma A, Noda N.
    Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
    [Abstract] [Full Text] [Related]

  • 34. Long-term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rate.
    Fyles GM, Messner HA, Lockwood G, Curtis JE, Rider W, Minden MD, Meharchand JM, Lipton J, Tritchler D, Van Dyk J.
    Bone Marrow Transplant; 1991 Dec; 8(6):453-63. PubMed ID: 1790425
    [Abstract] [Full Text] [Related]

  • 35. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide.
    Bostrom B, Weisdorf DJ, Kim T, Kersey JH, Ramsay NK.
    Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007
    [Abstract] [Full Text] [Related]

  • 36. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
    Matsuyama T, Kojima S, Kato K.
    Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
    [Abstract] [Full Text] [Related]

  • 37. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
    Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, Lamb LS.
    Bone Marrow Transplant; 2007 Jun; 39(12):751-7. PubMed ID: 17450185
    [Abstract] [Full Text] [Related]

  • 38. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
    Lee SH, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K.
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):122-8. PubMed ID: 15682073
    [Abstract] [Full Text] [Related]

  • 39. Prognostic factors affecting leukemia relapse after allogeneic BMT conditioned with cyclophosphamide and fractionated TBI.
    Zapatero A, Martín de Vidales C, Pinar B, Rodríguez F, Marín A, Cerezo L, Domínguez P, Pérez Torrubia A.
    Bone Marrow Transplant; 1996 Sep; 18(3):591-6. PubMed ID: 8879623
    [Abstract] [Full Text] [Related]

  • 40. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T, Van Lint MT, Gualandi F, Occhini D, Barbanti M, Sacchi N, Ficai G, Ghinatti C, Ferrara GB, Delfino L, Pozzi S, Morabito A, Zikos P, Vitale V, Corvo R, Frassoni F, Bacigalupo A.
    Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.